Evidence map›Paper›PMID 39585406›Full record

ReviewHerzschrittmachertherapie & Elektrophysiologie2024

[Everyone over the age of 65 years should wear a smartwatch : Pro and contra].

V Johnson, L Eckardt

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Herzschrittmachertherapie & Elektrophysiologie, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

V JohnsonUniversitäres Herzzentrum, ZIM - Med. Klinik 3 - Kardiologie, Angiologie, Universitätsmedizin Frankfurt, Theodor-Stern-Kai 7, 60596, Frankfurt am Main, Deutschland. victoria.johnson@herz-frankfurt.de.
L EckardtKlinik für Kardiologie II - Rhythmologie, Universitätsklinikum Münster, Albert-Schweitzer-Straße 33, Münster, Deutschland. lars.eckardt@ukmuenster.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atrial fibrillation (AF) is one of the most common cardiac arrhythmias and has far-reaching consequences not only for patients, but also for our healthcare system. The prevalence of this condition is expected to double in the coming decades. On the one hand, this is due to our aging population, the increasing number of comorbidities, and the improved technical possibilities for detection. A major complication of AF is stroke, whereby at-risk patients can be protected by oral anticoagulation if AF is diagnosed. The extent to which continuous screening for AF in patients with an increased risk of thromboembolic events should be carried out using wearables remains an important point in the current debate.

Indexed as

Atrial FibrillationAgedAged, 80 and overEvidence-Based MedicineFemaleGermanyHumansMaleMass ScreeningMobile ApplicationsStrokeWearable Electronic DevicesAnticoagulantsAtrial fibrillationCardiac arrhythmiasDiagnostics of arrhythmiasPhotoplethysmographyScreening

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.